Weihai Baihe Biology Technological's (SHSE:603102) Problems Go Beyond Weak Profit
Weihai Baihe Biology Technological's (SHSE:603102) Problems Go Beyond Weak Profit
The subdued market reaction suggests that Weihai Baihe Biology Technological Co., Ltd.'s (SHSE:603102) recent earnings didn't contain any surprises. We think that investors are worried about some weaknesses underlying the earnings.
市场反应平淡表明威海百合生物技术有限公司(SHSE:603102)最近的收益没有任何意外。我们认为投资者担心一些潜在的盈利弱点。
The Impact Of Unusual Items On Profit
除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。
For anyone who wants to understand Weihai Baihe Biology Technological's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥13m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If Weihai Baihe Biology Technological doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
对于想要了解威海百合生物技术超过法定数字的利润的人,重要的是要注意,在过去12个月里,法定利润中的1300万人民币来自于飞凡项目。我们不得不承认,更高的利润通常让我们感到乐观,但我们更希望利润能够持续。当我们分析全球大多数上市公司时,我们发现重大的飞凡项目通常不会重复。毕竟,这正是会计术语所暗示的。如果威海百合生物技术未能看到该贡献重复,那么其他条件不变,我们预计其今年的利润会下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Weihai Baihe Biology Technological.
注意:我们始终建议投资者检查资产负债表的实力。点击这里查看我们对威海百合生物技术资产负债表分析。
Our Take On Weihai Baihe Biology Technological's Profit Performance
我们对威海百合生物技术的利润表现的看法
We'd posit that Weihai Baihe Biology Technological's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Therefore, it seems possible to us that Weihai Baihe Biology Technological's true underlying earnings power is actually less than its statutory profit. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. You'd be interested to know, that we found 1 warning sign for Weihai Baihe Biology Technological and you'll want to know about it.
我们认为威海百和生物科技的法定收入并不是对持续生产力的清晰指标,因为存在大额飞凡项目。因此,我们认为威海百和生物科技的真正基本收入实际上可能低于其法定利润。更糟糕的是,其每股收益在过去一年内下降。最终,如果您想正确了解这家公司,除了上述因素外,还需要考虑更多因素。请记住,分析股票时需要注意相关风险。您可能会感兴趣的是,我们发现了威海百和生物科技的1个风险警示信号,您会想知道的。
Today we've zoomed in on a single data point to better understand the nature of Weihai Baihe Biology Technological's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天我们关注了单一的数据点,以更好地了解威海百和生物科技利润的性质。但还有许多其他方法可以了解公司。一些人认为股权回报率高是公司质量良好的一个征兆。因此,您可能希望查看提供高股权回报率的公司的免费收藏,或者股权所有权高的股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。